Skip to main content
TipRanks
Go Ultimate75% OFF

Polomar Health Services (PMHS) AI Stock Analysis

11 Followers
PMHS

Polomar Health Services

(Other OTC:PMHS)

Select Model
Rating:41Neutral
Price Target:$0.10â–¼(-4.76% Downside)
Action:reiterated
Date:11/11/26

The score is pressured primarily by weak financial performance—extreme operating/net losses, negative equity, and negative free cash flow—despite strong revenue growth and healthy gross margin. Technicals also reflect a weak downtrend with the stock trading below major moving averages. Valuation provides limited support because the company is unprofitable (negative P/E) and no dividend yield is indicated.

Positive Factors
Revenue GrowthThe sharp increase in trailing revenue indicates that Polomar is generating substantially more business than in the prior period. If maintained, this expanding revenue base could improve operating leverage and provide a foundation for narrowing losses, although current results do not yet show that benefit.
Negative Factors
Extreme Operating LossesThe scale of operating and net losses shows that the current cost structure is not supporting a viable earnings model, despite strong revenue growth and gross margin. Persistent losses can consume capital, restrict strategic investment, and require substantial restructuring before growth translates into durable profitability.

Polomar Health Services (PMHS) vs. SPDR S&P 500 ETF (SPY)

-200%0%200%400%600%800%1000%PMHS+31.25%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.98M
Dividend Yield
―
Average Volume (3M)
15.91K
Price to Earnings (P/E)
-0.3
Beta (1Y)
-0.53
Revenue Growth
7688.77%
EPS Growth
-359.43%
Country
US
Employees
7
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Polomar Health Services Business Overview & Revenue Model

Company Description

Polomar Health Services, Inc. operates as a retail compounding pharmacy. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded wi...

How the Company Makes Money

null

Polomar Health Services Financial Statement Overview

Summary

Despite sharp TTM revenue growth (~92%) and a solid gross margin (~61%), results are dominated by extremely large operating and net losses (operating margin ~-300%, net margin ~-301%), negative stockholders’ equity, and ongoing negative operating/free cash flow. Zero reported debt reduces leverage risk, but the balance sheet remains fragile and the company appears reliant on external funding.

Income Statement

12Very Negative

Balance Sheet

18Very Negative

Cash Flow

14Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.17M648.23K58.82K034.53K0
Gross Profit1.94M460.10K30.90K034.53K0
EBITDA-85.97K-776.94K-1.04M-410.66K-181.45K-132.75K
Net Income-9.46M-10.70M-1.34M-416.50K-181.12K-168.40K
Balance Sheet
Total Assets814.73K390.04K9.95M244261.48K0
Cash, Cash Equivalents and Short-Term Investments178.87K132.15K6,191244225.62K0
Total Debt794.79K14.86K49.18K81.66K69.70K32.69K
Total Liabilities1.87M1.61M14.86K13.78K74.72K35.65K
Stockholders Equity-1.06M-1.22M9.94M-13.54K186.77K-35.65K
Cash Flow
Free Cash Flow-6,956-396.00K-1.11M-371.86K-40.93K-32.69K
Operating Cash Flow-6,956-396.00K-1.02M-371.86K-40.93K-32.69K
Investing Cash Flow00-90.89K000
Financing Cash Flow181.15K521.95K1.11M146.49K266.55K32.69K

Polomar Health Services Technical Analysis

Technical Analysis SentimentNegative
Last Price0.10

Price Trends

50DMA0.16Negative
100DMA0.16Negative
200DMA0.17Negative

Market Momentum

MACD-0.01Positive
RSI35.35Neutral
STOCH-7.41Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMHS, the sentiment is Negative. The current price of 0.10 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.16, and below the 200-day MA of 0.17, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 35.35 is Neutral, neither overbought nor oversold. The STOCH value of -7.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PMHS.

Polomar Health Services Risk Analysis

Polomar Health Services disclosed 47 risk factors in its most recent earnings report. Polomar Health Services reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our largest shareholder and its affiliates have substantial control over us and our policies and will be able to influence all corporate matters, which might not be in other shareholders' interests.Q4, 2024
2.If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.Q4, 2024
3.A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.Q4, 2024

Polomar Health Services Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

PMHS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BJDXBJDX44Neutral$2.41M-0.09-113.80%――95.46%
MNDRMNDR43Neutral$1.11M-0.04-27.32%―4.47%92.03%
PMHSPMHS41Neutral$2.98M-0.301369.36%―7688.77%-359.43%
PRFXPRFX37Underperform$2.01M-0.06-72.87%―――
UPCUPC37Underperform$7.84M-0.41-3.48%―-8.04%-100.01%

* Healthcare Sector Average

Performance Comparison

0%250%500%750%PMHSPRFXUPCBJDXNIVFMNDRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PMHS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PMHSPolomar Health Services, Inc.0.100.0231.25%
PRFXPainreform Ltd.0.66-3.76-85.05%
UPCUniverse Pharmaceuticals Incorporation1.56-2.01-56.30%
BJDXBluejay Diagnostics, Inc.2.15-20.56-90.51%
NIVFNewgenivf Group Limited0.17-5681.49-100.00%
MNDRMobile-health Network Solutions Class A0.93-9.03-90.66%

Polomar Health Services Corporate Events

Business Operations and StrategyExecutive/Board Changes

Polomar Health Services Streamlines Board After Director Resignations

Neutral
Oct 19, 2026

On October 14, 2026, Polomar Health Services, Inc. saw the resignation of two board members, Alexandra Peterson from the Audit Committee and Gabrielle Toledano from the Compensation Committee, with the Board notified on October 15, 2026. The company...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026